Pfizer announced Friday that it has halted the testing of a twice daily obesity drug due to side effects. In a press statement, the company announced that it will focus its future efforts on the drug danuglipron to a “once daily formulation”. It noted that the Phase 2b clinical trials showed high rates of adverse effects with the twice-daily formula.
Pfizer announced on Friday that it will stop testing a twice-daily anti-obesity medication due to side effects. In a press release, the company announced that it would then concentrate all of its upcoming research and development efforts on danuglipron’s “once-daily formulation.” In its Phase 2b medical trial, it found high rates of adverse reactions to the twice-daily formulation… Pfizer announced on Friday that it will stop testing a twice-daily anti-obesity medication due to side effects. In a press release, the company announced that it would presently concentrate all of its upcoming research and development efforts on danuglipron’s “once-daily formulation.” In its Phase 2b clinical trial, it discovered higher rates of adverse reactions to the twice-daily formulation…
Pfizer announced Friday that it has halted the testing of a twice daily obesity drug due to side effects. In a press statement, the company announced that it will focus its future efforts on the drug danuglipron to a “once daily formulation”. It noted that the Phase 2b clinical trials showed high rates of adverse effects with the twice-daily formula.
